The case for & against
Bull & Bear analysis
Kyntra Bio, Inc. (NASDAQ: KYNB) is an emerging biopharmaceutical company focused on advancing innovative biologics for the treatment of various cancers, including metastatic castration-resistant prostate cancer (MCRPC) and anemia associated with lower-risk myelodysplastic syndromes (MDS). The company is strategically positioned within the oncology sector, addressing significant unmet medical needs through its clinical pipeline, which includes FG3246, a potential first-in-class antibody-drug conjugate, and Roxidustat, aimed at treating anemia. With ongoing clinical trials and a robust cash position, Kyntra Bio aims to establish itself as a key player in the oncology treatment landscape.
Bull says
- ↑Cash position of $95.7M funds operations into 2028
- ↑Q2 2026 net income of $12M vs. $13.7M loss prior year
- ↑FG3246 interim analysis due Q4 2026; Roxidustat Phase III trial slated late 2026
- ↑Roxidustat targets unmet anemia needs in >50% of lower-risk MDS patients
- ↑Exploring Roxidustat partnerships while reinforcing in-house development
- ↑Adequate liquidity and moderate leverage support long-term upside
Bear says
- ↓P/S ratio of 6.82 implies ~65% overvaluation
- ↓Q2 2026 revenue of –$1.5M vs. $1.3M prior year
- ↓Negative cash flow and unprofitability weigh on valuation
- ↓Earnings yield and profitability factors are deeply negative
- ↓Enrollment and competition risks could delay trial milestones
- ↓Weak momentum and small-cap profile may deter investors
Earnings Call · Q4 2025 · Mgmt. Guidance
Transcript signals
Bull points
- We completed the sale of Hybrids in China to AstraZeneca, paid off our senior secure term loan, and extended our cash runway into 2028.
- We remain confident that with our mid and late stage assets, simplified capital structure, and upcoming catalysts across both clinical programs, we are well positioned to create meaningful therapeutic options for patients and significant value for shareholders.
- We believe FG3246 could be this new treatment option and estimate the total addressable market to be well over $5 billion annually in the US alone.
Bear points
- clearly we don't have the kind of expertise in this space that companies like Telex and Lantheus have.
- For the fourth quarter of 2025, total revenue was $1.3 million compared to $3.1 million for the same period in 2024.
- For a full year 2025, total revenue was $6.4 million compared to $29.6 million for the full year 2024.